Celcuity Inc. will participate in the Stifel 2025 Healthcare Conference with a fireside chat on November 11, 2025.
Quiver AI Summary
Celcuity Inc., a clinical-stage biotechnology company focused on targeted oncology therapies, will participate in the Stifel 2025 Healthcare Conference in New York from November 11-13, 2025. CEO Brian Sullivan will have a fireside chat on November 11 at 10:00 a.m. ET, which will be available via live webcast. The company is advancing its lead therapeutic candidate, gedatolisib, a pan-PI3K and mTORC1/2 inhibitor, through various clinical trials, including Phase 3 studies VIKTORIA-1 and VIKTORIA-2 for HR+/HER2- advanced breast cancer, as well as an ongoing Phase 1/2 trial for prostate cancer. More information can be found on their website and through ClinicalTrials.gov.
Potential Positives
- Celcuity's participation in the prestigious Stifel 2025 Healthcare Conference highlights the company's visibility and credibility within the biotechnology and healthcare sectors.
- Brian Sullivan, the CEO and Co-founder, will engage in a fireside chat, providing an opportunity to share significant updates and insights about the company's developments and future direction.
- The ongoing Phase 3 clinical trials (VIKTORIA-1 and VIKTORIA-2) for gedatolisib position Celcuity as a key player in oncology, particularly in treating HR+/HER2- advanced breast cancer.
- The mention of the differentiated mechanism of action of gedatolisib suggests potential competitive advantages for the company's therapeutic candidate over existing treatments.
Potential Negatives
- The company did not provide any updates on the specific results or timelines of ongoing clinical trials, which could raise concerns among investors regarding the progress of their lead therapeutic candidate, gedatolisib.
- Participation in a conference may imply the company is seeking to boost visibility, potentially signaling a need for investor confidence in light of existing uncertainties regarding clinical outcomes.
- The press release lacks information on any strategic partnerships or collaborations that might strengthen the company's market position, which could be viewed as a weakness in a competitive biotech landscape.
FAQ
When is Celcuity participating in the Stifel 2025 Healthcare Conference?
Celcuity will participate in the conference from November 11-13, 2025, with a fireside chat on November 11 at 10:00 a.m. ET.
Who will represent Celcuity at the conference?
Brian Sullivan, Chief Executive Officer and Co-founder of Celcuity, will represent the company at the event.
How can I watch the Celcuity presentation live?
A live webcast of the event can be accessed at the provided link or from the Investors section of Celcuity's website.
What is gedatolisib?
Gedatolisib is Celcuity’s lead therapeutic candidate, acting as a pan-PI3K and mTORC1/2 inhibitor targeting the PAM pathway.
Where can I find more information about Celcuity's clinical trials?
More detailed information about Celcuity’s active clinical trials is available on ClinicalTrials.gov.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CELC Insider Trading Activity
$CELC insiders have traded $CELC stock on the open market 11 times in the past 6 months. Of those trades, 4 have been purchases and 7 have been sales.
Here’s a breakdown of recent trading of $CELC stock by insiders over the last 6 months:
- BROS. ADVISORS LP BAKER has made 4 purchases buying 170,100 shares for an estimated $9,571,318 and 0 sales.
- DAVID DALVEY has made 0 purchases and 7 sales selling 109,325 shares for an estimated $4,818,369.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$CELC Hedge Fund Activity
We have seen 65 institutional investors add shares of $CELC stock to their portfolio, and 41 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BAKER BROS. ADVISORS LP added 1,192,710 shares (+28.0%) to their portfolio in Q2 2025, for an estimated $15,922,678
- NEA MANAGEMENT COMPANY, LLC added 1,044,260 shares (+83.5%) to their portfolio in Q2 2025, for an estimated $13,940,871
- JANUS HENDERSON GROUP PLC removed 796,981 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $10,639,696
- PERCEPTIVE ADVISORS LLC removed 729,071 shares (-30.9%) from their portfolio in Q2 2025, for an estimated $9,733,097
- SOLEUS CAPITAL MANAGEMENT, L.P. added 437,696 shares (+17.0%) to their portfolio in Q2 2025, for an estimated $5,843,241
- BALYASNY ASSET MANAGEMENT L.P. added 239,504 shares (+inf%) to their portfolio in Q2 2025, for an estimated $3,197,378
- CITADEL ADVISORS LLC removed 194,275 shares (-20.5%) from their portfolio in Q2 2025, for an estimated $2,593,571
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$CELC Analyst Ratings
Wall Street analysts have issued reports on $CELC in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 10/22/2025
- Needham issued a "Buy" rating on 10/20/2025
- Guggenheim issued a "Buy" rating on 09/22/2025
- Leerink Partners issued a "Outperform" rating on 07/28/2025
- Stifel issued a "Buy" rating on 07/01/2025
To track analyst ratings and price targets for $CELC, check out Quiver Quantitative's $CELC forecast page.
$CELC Price Targets
Multiple analysts have issued price targets for $CELC recently. We have seen 5 analysts offer price targets for $CELC in the last 6 months, with a median target of $70.0.
Here are some recent targets:
- Swayampakula Ramakanth from HC Wainwright & Co. set a target price of $77.0 on 10/22/2025
- Gil Blum from Needham set a target price of $70.0 on 10/20/2025
- Brad Canino from Guggenheim set a target price of $110.0 on 09/22/2025
- Andrew Berens from Leerink Partners set a target price of $60.0 on 07/28/2025
- Stephen Willey from Stifel set a target price of $30.0 on 07/01/2025
Full Release
MINNEAPOLIS, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its participation in the Stifel 2025 Healthcare Conference to be held in New York on November 11-13, 2025.
Brian Sullivan, Chief Executive Officer, and Co-founder of Celcuity, is scheduled for a fireside chat at 10:00 a.m. ET on Tuesday, November 11, 2025. A live webcast of the event will be available using this weblink https://event.summitcast.com/view/cwkmPXkC4dosg6MoG95rxb/TdhPBfiMCSQpwPu5E5FzDS . Alternatively, the live webcast will be accessible from the Investors section of the company's website at https://ir.celcuity.com/events-presentations/ with a replay available shortly after.
About Celcuity
Celcuity is a clinical-stage biotechnology company pursuing development of targeted therapies for treatment of multiple solid tumor indications. The company's lead therapeutic candidate is gedatolisib, a potent, pan-PI3K and mTORC1/2 inhibitor that comprehensively blockades the PI3K/AKT/mTOR (“PAM”) pathway. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3Kα, AKT, or mTORC1 alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- ABC has completed enrollment and reported detailed results for the PIK3CA Wild-Type cohort and has completed enrollment of patients for the PIK3CA mutant cohort. A Phase 3 clinical trial, VIKTORIA-2, evaluating gedatolisib plus a CDK4/6 inhibitor and fulvestrant as first-line treatment for patients with HR+/HER2- ABC is currently enrolling patients. A Phase 1/2 clinical trial, CELC-G-201, evaluating gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer, is ongoing. More detailed information about Celcuity’s active clinical trials can be found at ClinicalTrials.gov . Celcuity is headquartered in Minneapolis. Further information about Celcuity can be found at www.celcuity.com . Follow us on LinkedIn and X .
View source version of release on GlobeNewswire.com
Contacts:
Celcuity Inc.
Brian Sullivan,
[email protected]
Vicky Hahne,
[email protected]
(763) 392-0123
ICR Healthcare
Patti Bank, [email protected]
(415) 513-1284
